The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom
Abstract Introduction Data on the burden of hypereosinophilic syndrome (HES) are limited. This study investigated the incidence and prevalence of HES using real‐world data from patients in the United Kingdom. Methods Primary care data from the Clinical Practice Research Datalink were analyzed. The p...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.495 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850074409509847040 |
|---|---|
| author | Gema Requena John Logie Daniel C. Gibbons Jonathan Steinfeld Melissa K. Van Dyke |
| author_facet | Gema Requena John Logie Daniel C. Gibbons Jonathan Steinfeld Melissa K. Van Dyke |
| author_sort | Gema Requena |
| collection | DOAJ |
| description | Abstract Introduction Data on the burden of hypereosinophilic syndrome (HES) are limited. This study investigated the incidence and prevalence of HES using real‐world data from patients in the United Kingdom. Methods Primary care data from the Clinical Practice Research Datalink were analyzed. The patients of interest were identified using medical codes specific for HES. Annual incidence rates and prevalence were estimated for the years 2010–2018 (inclusive) using patients observed for a minimum period of one year. Results Between 2010 and 2018, 93 patients were identified with HES. During the study period the incidence of HES ranged from less than 0.04, 95% confidence interval (CI) (0.01–0.07) to 0.17, 95% CI (0.10–0.26) per 100,000 person‐years and the prevalence ranged from 0.15, 95% CI (0.10–0.25) to 0.89, 95% CI (0.74–1.09) cases per 100,000 persons. Sensitivity analyses varying the minimum observation period required to identify HES patients gave similar results. Conclusion These results provide estimates of the burden of HES in the United Kingdom and indicate that whilst HES is a very rare disease, there is evidence that is increasingly being recorded in UK primary care. |
| format | Article |
| id | doaj-art-bb846459b2d146bca141be52aa8e96d5 |
| institution | DOAJ |
| issn | 2050-4527 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-bb846459b2d146bca141be52aa8e96d52025-08-20T02:46:35ZengWileyImmunity, Inflammation and Disease2050-45272021-12-01941447145110.1002/iid3.495The increasing incidence and prevalence of hypereosinophilic syndrome in the United KingdomGema Requena0John Logie1Daniel C. Gibbons2Jonathan Steinfeld3Melissa K. Van Dyke4Epidemiology, Value Evidence and Outcomes, Global R&D, GSK London UKReal World Analytics, Value Evidence and Outcomes, Global Medical, GSK London UKReal World Analytics, Value Evidence and Outcomes, Global Medical, GSK London UKRespiratory Research & Development, GSK Collegeville Pennsylvania USAEpidemiology, Value Evidence and Outcomes, Global R&D, GSK Collegeville Pennsylvania USAAbstract Introduction Data on the burden of hypereosinophilic syndrome (HES) are limited. This study investigated the incidence and prevalence of HES using real‐world data from patients in the United Kingdom. Methods Primary care data from the Clinical Practice Research Datalink were analyzed. The patients of interest were identified using medical codes specific for HES. Annual incidence rates and prevalence were estimated for the years 2010–2018 (inclusive) using patients observed for a minimum period of one year. Results Between 2010 and 2018, 93 patients were identified with HES. During the study period the incidence of HES ranged from less than 0.04, 95% confidence interval (CI) (0.01–0.07) to 0.17, 95% CI (0.10–0.26) per 100,000 person‐years and the prevalence ranged from 0.15, 95% CI (0.10–0.25) to 0.89, 95% CI (0.74–1.09) cases per 100,000 persons. Sensitivity analyses varying the minimum observation period required to identify HES patients gave similar results. Conclusion These results provide estimates of the burden of HES in the United Kingdom and indicate that whilst HES is a very rare disease, there is evidence that is increasingly being recorded in UK primary care.https://doi.org/10.1002/iid3.495hypereosinophilic syndromeincidenceprevalenceUnited Kingdom |
| spellingShingle | Gema Requena John Logie Daniel C. Gibbons Jonathan Steinfeld Melissa K. Van Dyke The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom Immunity, Inflammation and Disease hypereosinophilic syndrome incidence prevalence United Kingdom |
| title | The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom |
| title_full | The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom |
| title_fullStr | The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom |
| title_full_unstemmed | The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom |
| title_short | The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom |
| title_sort | increasing incidence and prevalence of hypereosinophilic syndrome in the united kingdom |
| topic | hypereosinophilic syndrome incidence prevalence United Kingdom |
| url | https://doi.org/10.1002/iid3.495 |
| work_keys_str_mv | AT gemarequena theincreasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT johnlogie theincreasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT danielcgibbons theincreasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT jonathansteinfeld theincreasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT melissakvandyke theincreasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT gemarequena increasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT johnlogie increasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT danielcgibbons increasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT jonathansteinfeld increasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom AT melissakvandyke increasingincidenceandprevalenceofhypereosinophilicsyndromeintheunitedkingdom |